Detalhe da pesquisa
1.
Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
J Eur Acad Dermatol Venereol
; 38(1): e102-e105, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611255
2.
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience.
Actas Dermosifiliogr
; 114(4): 363-365, 2023 04.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36549381
3.
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience. / [Artículo traducido] Los inhibidores selectivos de la IL23 son, en su mayoría, efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas.
Actas Dermosifiliogr
; 114(4): T363-T365, 2023 04.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-36804910
4.
Widespread purpura annularis telangiectodes following mRNA SARS-CoV-2 vaccine.
J Eur Acad Dermatol Venereol
; 35(11): e719-e721, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236717
5.
Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry.
J Eur Acad Dermatol Venereol
; 35(10): e624-e626, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34062018
6.
The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases.
J Eur Acad Dermatol Venereol
; 34(10): e574-e576, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32526040